Development of quantitative molecular clinical end points for siRNA clinical trials

Robyn P. Hickerson, Sancy Leachman, Lana N. Pho, Emilio Gonzalez-Gonzalez, Frances J D Smith, W. H Irwin McLean, Christopher H. Contag, Devin Leake, Leonard M. Milstone, Roger L. Kaspar

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single nucleotide-specific siRNA (K6a-513a.12, also known as TD101) was recently evaluated in a phase 1b clinical trial for the rare skin disorder, pachyonychia congenita (PC). To develop a clinical trial molecular end point for this type of trial, methods were developed to: (1) isolate total RNA containing amplifiable mRNA from human skin and callus material; (2) quantitatively distinguish the single-nucleotide mutant mRNA from wild-type K6a mRNA in both patient-derived keratinocytes and patient callus; and (3) demonstrate that repeated siRNA treatment results in sustained inhibition of mutant K6a mRNA in patient-derived keratinocyte cultures. These methods allow noninvasive sampling and monitoring of gene expression from patient-collected shavings and may be useful in evaluating the effectiveness of RNAi-based therapeutics, including inhibitors that specifically target single-nucleotide mutations.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalJournal of Investigative Dermatology
Volume131
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Small Interfering RNA
Clinical Trials
Messenger RNA
Nucleotides
Bony Callus
RNA
RNA Interference
Keratinocytes
Skin
Pachyonychia Congenita
Gene Expression Profiling
Gene expression
Therapeutics
Genes
Sampling
Mutation
Monitoring

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Hickerson, R. P., Leachman, S., Pho, L. N., Gonzalez-Gonzalez, E., Smith, F. J. D., McLean, W. H. I., ... Kaspar, R. L. (2011). Development of quantitative molecular clinical end points for siRNA clinical trials. Journal of Investigative Dermatology, 131(5), 1029-1036. https://doi.org/10.1038/jid.2010.372

Development of quantitative molecular clinical end points for siRNA clinical trials. / Hickerson, Robyn P.; Leachman, Sancy; Pho, Lana N.; Gonzalez-Gonzalez, Emilio; Smith, Frances J D; McLean, W. H Irwin; Contag, Christopher H.; Leake, Devin; Milstone, Leonard M.; Kaspar, Roger L.

In: Journal of Investigative Dermatology, Vol. 131, No. 5, 05.2011, p. 1029-1036.

Research output: Contribution to journalArticle

Hickerson, RP, Leachman, S, Pho, LN, Gonzalez-Gonzalez, E, Smith, FJD, McLean, WHI, Contag, CH, Leake, D, Milstone, LM & Kaspar, RL 2011, 'Development of quantitative molecular clinical end points for siRNA clinical trials', Journal of Investigative Dermatology, vol. 131, no. 5, pp. 1029-1036. https://doi.org/10.1038/jid.2010.372
Hickerson, Robyn P. ; Leachman, Sancy ; Pho, Lana N. ; Gonzalez-Gonzalez, Emilio ; Smith, Frances J D ; McLean, W. H Irwin ; Contag, Christopher H. ; Leake, Devin ; Milstone, Leonard M. ; Kaspar, Roger L. / Development of quantitative molecular clinical end points for siRNA clinical trials. In: Journal of Investigative Dermatology. 2011 ; Vol. 131, No. 5. pp. 1029-1036.
@article{3258bfce47af4a42ad0a25cb129cc96f,
title = "Development of quantitative molecular clinical end points for siRNA clinical trials",
abstract = "RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single nucleotide-specific siRNA (K6a-513a.12, also known as TD101) was recently evaluated in a phase 1b clinical trial for the rare skin disorder, pachyonychia congenita (PC). To develop a clinical trial molecular end point for this type of trial, methods were developed to: (1) isolate total RNA containing amplifiable mRNA from human skin and callus material; (2) quantitatively distinguish the single-nucleotide mutant mRNA from wild-type K6a mRNA in both patient-derived keratinocytes and patient callus; and (3) demonstrate that repeated siRNA treatment results in sustained inhibition of mutant K6a mRNA in patient-derived keratinocyte cultures. These methods allow noninvasive sampling and monitoring of gene expression from patient-collected shavings and may be useful in evaluating the effectiveness of RNAi-based therapeutics, including inhibitors that specifically target single-nucleotide mutations.",
author = "Hickerson, {Robyn P.} and Sancy Leachman and Pho, {Lana N.} and Emilio Gonzalez-Gonzalez and Smith, {Frances J D} and McLean, {W. H Irwin} and Contag, {Christopher H.} and Devin Leake and Milstone, {Leonard M.} and Kaspar, {Roger L.}",
year = "2011",
month = "5",
doi = "10.1038/jid.2010.372",
language = "English (US)",
volume = "131",
pages = "1029--1036",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Development of quantitative molecular clinical end points for siRNA clinical trials

AU - Hickerson, Robyn P.

AU - Leachman, Sancy

AU - Pho, Lana N.

AU - Gonzalez-Gonzalez, Emilio

AU - Smith, Frances J D

AU - McLean, W. H Irwin

AU - Contag, Christopher H.

AU - Leake, Devin

AU - Milstone, Leonard M.

AU - Kaspar, Roger L.

PY - 2011/5

Y1 - 2011/5

N2 - RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single nucleotide-specific siRNA (K6a-513a.12, also known as TD101) was recently evaluated in a phase 1b clinical trial for the rare skin disorder, pachyonychia congenita (PC). To develop a clinical trial molecular end point for this type of trial, methods were developed to: (1) isolate total RNA containing amplifiable mRNA from human skin and callus material; (2) quantitatively distinguish the single-nucleotide mutant mRNA from wild-type K6a mRNA in both patient-derived keratinocytes and patient callus; and (3) demonstrate that repeated siRNA treatment results in sustained inhibition of mutant K6a mRNA in patient-derived keratinocyte cultures. These methods allow noninvasive sampling and monitoring of gene expression from patient-collected shavings and may be useful in evaluating the effectiveness of RNAi-based therapeutics, including inhibitors that specifically target single-nucleotide mutations.

AB - RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single nucleotide-specific siRNA (K6a-513a.12, also known as TD101) was recently evaluated in a phase 1b clinical trial for the rare skin disorder, pachyonychia congenita (PC). To develop a clinical trial molecular end point for this type of trial, methods were developed to: (1) isolate total RNA containing amplifiable mRNA from human skin and callus material; (2) quantitatively distinguish the single-nucleotide mutant mRNA from wild-type K6a mRNA in both patient-derived keratinocytes and patient callus; and (3) demonstrate that repeated siRNA treatment results in sustained inhibition of mutant K6a mRNA in patient-derived keratinocyte cultures. These methods allow noninvasive sampling and monitoring of gene expression from patient-collected shavings and may be useful in evaluating the effectiveness of RNAi-based therapeutics, including inhibitors that specifically target single-nucleotide mutations.

UR - http://www.scopus.com/inward/record.url?scp=79954616664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954616664&partnerID=8YFLogxK

U2 - 10.1038/jid.2010.372

DO - 10.1038/jid.2010.372

M3 - Article

C2 - 21191405

AN - SCOPUS:79954616664

VL - 131

SP - 1029

EP - 1036

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 5

ER -